Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Geron Restructuring Sours Investors As Company Bets On Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

The pioneering U.S. biotech will look to partner its five human embryonic stem cell research programs while focusing entirely on two mid-stage cancer assets.

Advertisement

Related Content

Geron CEO: Getting Imetelstat Data Wanted By FDA Will Be “Difficult”
For Cutting-Edge Stem Cell Work, California Billions Still Unmatched
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Osiris Prochymal Gets Green Light In Canada; FDA Filing Is Next
GSK Pays $31.5 Million Upfront, Plus Milestones To Access Angiochem’s Rare Disease Technologies
Curis Teams Up With LLS To Fund Early-Stage Research
Deals Of The Week: Cephalon/Mesoblast; GSK/MeiRui; Geron/Angiochem…
Beijing Firm Launches Clinical Trial On Stem Cell Treatment For Diabetes
Onyx Sees Blockbuster In Oncology Drug Carflizomib, Buys Proteolix To Get It
Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel